These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 30448451)

  • 41. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes.
    Güneş E; Güneş M
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6691-6699. PubMed ID: 37522680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
    J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
    Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
    [No Abstract]   [Full Text] [Related]  

  • 46. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
    Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.
    Mehta R; Chen R; Hirose T; John M; Kok A; Lehmann R; Unnikrishnan AG; Yavuz DG; Fulcher G
    Diabetes Obes Metab; 2020 Nov; 22(11):1961-1975. PubMed ID: 32618405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
    Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
    Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.
    Kisioglu SV; Demir AS; Tufekci D; Emur Gunay Y; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
    Int J Clin Pract; 2021 Sep; 75(9):e14377. PubMed ID: 34003539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
    Fulcher GR; Akhtar S; Al-Jaser SJ; Medina J; Mohamed M; Nicodemus NA; Olsen AH; Singh KP; Kok A
    Adv Ther; 2022 Aug; 39(8):3735-3748. PubMed ID: 35752730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overview of Clinical Trial Program and Applicability of Insulin Degludec/Insulin Aspart in Diabetes Management.
    Bantwal G; Wangnoo SK; Shunmugavelu M; Nallaperumal S; Harsha KP; Bhattacharyya A
    J Assoc Physicians India; 2015 May; 63(5 Suppl):21-8. PubMed ID: 26548031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.
    Hirose T; Awata T; Yamamoto Y; Hemmingsen MP
    Expert Opin Biol Ther; 2018 Jan; 18(1):77-85. PubMed ID: 29017373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
    Ritzel R; Ghosh S; Emral R; Malek R; Zeng L; Mabunay MA; Landgraf W; Guyot P; Serafini P; Pushkarna D; Malik RA
    Diabetes Obes Metab; 2023 Sep; 25(9):2495-2504. PubMed ID: 37312665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
    Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
    Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
    Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
    Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
    Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
    Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
    Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
    Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS.
    Gerety G; Bebakar WM; Chaykin L; Ozkaya M; Macura S; Hersløv ML; Behnke T
    Endocr Pract; 2016 May; 22(5):546-54. PubMed ID: 26720250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.